=====RLIP76=====
Ral [[binding protein]] 1 (RLIP76) is a multifunctional [[protein]] that transports [[glutathione]]–electrophile conjugates as well as chemotherapy drugs across the [[plasmalemma]].

It is also required for diverse cellular functions such as mitosis, apoptosis and endocytosis and is overexpressed in a variety of malignancies 

The [[GTPase activating protein]] RLIP76 is overexpressed in and correlates with the pathological grade of many malignant tumor cells. 

It is a central regulator in multiple [[pathway]]s that respond to redox states and control cell growth, motility, division, and apoptosis in many malignant cancer cells.

The dramatic increases in cancer cell radio- and chemosensitivity induced by RNAi-mediated RLIP76 knockdown and RLIP76 antibody inhibition are mainly due to suppression of RLIP76 adenosine triphosphatase (ATPase)-dependent transporter activity, allowing accumulation of endogenously formed glutathione–electrophile conjugates and drugs that induce apoptosis in cancer cells. In addition to membrane transport, RLIP76 is a Rho-selective GTPase-activating protein (RhoGAP) and negative regulator of Cdc42 and Rac1
((Wang Q, Wang JY, Zhang XP, Lv ZW, Fu D, Lu YC, Hu GH, Luo C, Chen JX. RLIP76
is overexpressed in human glioblastomas and is required for proliferation,
tumorigenesis and suppression of apoptosis. Carcinogenesis. 2013
Apr;34(4):916-26. doi: 10.1093/carcin/bgs401. Epub 2012 Dec 30. PubMed PMID:
23276796.
)).

Inhibition of RLIP76 expression may be an effective means for overcoming RLIP76-associated chemoresistance in human malignant [[glioma]] cells and may represent a potential gene-targeting approach for glioma treatment
((Wang Q, Qian J, Wang J, Luo C, Chen J, Hu G, Lu Y. Knockdown of RLIP76
expression by RNA interference inhibits invasion, induces cell cycle arrest, and 
increases chemosensitivity to the anticancer drug temozolomide in glioma cells. J
Neurooncol. 2013 Mar;112(1):73-82. doi: 10.1007/s11060-013-1045-2. Epub 2013 Jan 
6. PubMed PMID: 23292182.
)).

RLIP76 expression is associated with a poor outcome of [[meningioma]] and may provide a new [[gene therapy]] approach for patients with [[malignant meningioma]]s
((Fan SY, Jiang JD, Qian J, Lu YC, Hu GH, Luo C, Hou WD, Wang Q. Overexpression 
of RLIP76 Required for Proliferation in Meningioma Is Associated with Recurrence.
PLoS One. 2015 May 20;10(5):e0125661. doi: 10.1371/journal.pone.0125661.
eCollection 2015. PubMed PMID: 25993541.
)).